Serum Immunoglobulin Changes in Multiple Myeloma Patients Treated with CAR T-Cell Therapy
{{output}}
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed or refractory multiple myeloma (RRMM), with high response rates of 80-95%. Serum immunoglobulin changes have been observed throughout conventional multiple myeloma... ...
